Document ID: chunk:federal_register_of_legislation:F2020C00213:body:0:p5
Version: federal_register_of_legislation:F2020C00213
Segment Type: other
Provision Reference: 
Character Range: 11227–14306

(u)                being exposed to arsenic as specified before the clinical onset of malignant neoplasm of the lung, where the first exposure to arsenic occurred at least ten years before the clinical onset of malignant neoplasm of the lung; or

         (v)                inhaling smoke from the combustion of coal, wood, charcoal or another solid biomass fuel while in an enclosed space with a visible smoke haze:

            (i)            for a cumulative period of at least 7 500 hours before the clinical onset of malignant neoplasm of the lung; and
            (ii)         where the first inhalation of smoke commenced at least five years before the clinical onset of malignant neoplasm of the lung; or

         (w)              inhaling ambient polluted air as specified:

            (i)            for a cumulative period of at least 35 000 hours before the clinical onset of malignant neoplasm of the lung; and
            (ii)         where the first inhalation of ambient polluted air occurred at least five years before the clinical onset of malignant neoplasm of the lung; or

         (x)                inhaling soot, whilst engaged in the cleaning of chimneys or flues:
            (i)            for a cumulative period of at least 1 500 hours before the clinical onset of malignant neoplasm of the lung; and
            (ii)         where the first inhalation of soot occurred at least five years before the clinical onset of malignant neoplasm of the lung; or

         (y)                inhaling mist from a strong inorganic acid:
            (i)            for a cumulative period of at least 1 500 hours before the clinical onset of malignant neoplasm of the lung; and
            (ii)         where the first inhalation of mist from a strong inorganic acid commenced at least five years before the clinical onset of malignant neoplasm of the lung; or

         (ya) inhaling, ingesting or having cutaneous contact with diazinon for a cumulative period of at least 1 000 hours before the clinical onset of malignant neoplasm of the lung, where the first exposure to diazinon occurred at least five years before the clinical onset of malignant neoplasm of the lung; or

         (z)                inhaling fumes in an enclosed space, while working in a specified industry or manufacturing process generating high concentrations of volatile polycyclic aromatic hydrocarbons:
            (i)            for a cumulative period of at least 1 500 hours before the clinical onset of malignant neoplasm of the lung; and
            (ii)         where the first inhalation of fumes occurred at least five years before the clinical onset of malignant neoplasm of the lung; or

         (aa)            inhaling fumes of a chemical substance from the specified list involving exposure to high levels of volatile polycyclic aromatic hydrocarbons:
            (i)            for a cumulative period of at least 1 500 hours before the clinical onset of malignant neoplasm of the lung; and
            (ii)         where the first inhalation of fumes occurred at